Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Comparative Evaluation of the Single-dose Efficacy of Oral Delafloxacin Versus the Single-dose Efficacy of an Intramuscular Injection of Ceftriaxone in Subjects With Uncomplicated Urogenital Gonorrhea

Next Previous
X
Search
Trial Profile

A Comparative Evaluation of the Single-dose Efficacy of Oral Delafloxacin Versus the Single-dose Efficacy of an Intramuscular Injection of Ceftriaxone in Subjects With Uncomplicated Urogenital Gonorrhea

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Delafloxacin (Primary) ; Ceftriaxone
  • Indications Gonorrhoea; Gram-negative infections; Neisseria infections
  • Focus Registrational; Therapeutic Use
  • Acronyms PROCEEDING
  • Sponsors Melinta Therapeutics

    • Most Recent Events

    • 18 Jan 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov
    • 13 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 18 Sep 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top